The Role of Traditional Chinese Medicines in the Treatment of Osteoporosis
- PMID: 38879748
- DOI: 10.1142/S0192415X24500393
The Role of Traditional Chinese Medicines in the Treatment of Osteoporosis
Abstract
Osteoporosis (OP) represents a substantial public health issue and is associated with increasing rates of morbidity and mortality. It is characterized by reduced bone mineral density, deterioration of bone tissue quality, disruption of the microarchitecture of bones, and compromised bone strength. These changes may be attributed to the following factors: intercellular communication between osteoblasts and osteoclasts; imbalanced bone remodeling; imbalances between osteogenesis and adipogenesis; imbalances in hormonal regulation; angiogenesis; chronic inflammation; oxidative stress; and intestinal microbiota imbalances. Treating a single aspect of the disease is insufficient to address its multifaceted nature. In recent decades, traditional Chinese medicine (TCM) has shown great potential in the treatment of OP, and the therapeutic effects of Chinese patent drugs and Chinese medicinal herbs have been scientifically proven. TCMs, which contain multiple components, can target the diverse pathogeneses of OP through a multitargeted approach. Herbs such as XLGB, JTG, GSB, Yinyanghuo, Gusuibu, Buguzhi, and Nvzhenzi are among the TCMs that can be used to treat OP and have demonstrated promising effects in this context. They exert their therapeutic effects by targeting various pathways involved in bone metabolism. These TCMs balance the activity of osteoblasts (bone-forming cells) and osteoclasts (bone-resorbing cells), and they exhibit anti-inflammatory, immunomodulatory, anti-oxidative, and estrogen-like functions. These multifaceted mechanisms underlie the efficacy of these herbs in the management and treatment of OP. Herein, we examine the efficacy of various Chinese herbs and Chinese patent drugs in treating OP by reviewing previous clinical trials and basic experiments, and we examine the potential mechanism of these therapies to provide evidence regarding the use of TCM for treating OP.
Keywords: Bioactive Constituents; Bone Remodeling; Mechanism; Osteoporosis; Review; Traditional Chinese Medicine.
Similar articles
-
Traditional Chinese medicine formulas for the treatment of osteoporosis: Implication for antiosteoporotic drug discovery.J Ethnopharmacol. 2016 Aug 2;189:61-80. doi: 10.1016/j.jep.2016.05.025. Epub 2016 May 11. J Ethnopharmacol. 2016. PMID: 27180315 Review.
-
The Nexus Between Traditional Chinese Medicine and Immunoporosis: Implications in the Treatment and Management of Osteoporosis.Phytother Res. 2025 Apr;39(4):1826-1846. doi: 10.1002/ptr.8397. Epub 2024 Dec 3. Phytother Res. 2025. PMID: 39625224 Review.
-
Rehmanniae Radix in osteoporosis: A review of traditional Chinese medicinal uses, phytochemistry, pharmacokinetics and pharmacology.J Ethnopharmacol. 2017 Feb 23;198:351-362. doi: 10.1016/j.jep.2017.01.021. Epub 2017 Jan 19. J Ethnopharmacol. 2017. PMID: 28111216 Review.
-
A new strategy for discovering effective substances and mechanisms of traditional Chinese medicine based on standardized drug containing plasma and the absorbed ingredients composition, a case study of Xian-Ling-Gu-Bao capsules.J Ethnopharmacol. 2021 Oct 28;279:114396. doi: 10.1016/j.jep.2021.114396. Epub 2021 Jul 8. J Ethnopharmacol. 2021. PMID: 34246738
-
Multitargeted combination effects of a triherbal formulation containing ELP against osteoporosis: in vitro evidence.J Pharm Pharmacol. 2016 Jun;68(6):826-33. doi: 10.1111/jphp.12542. Epub 2016 Mar 28. J Pharm Pharmacol. 2016. PMID: 27019348
Cited by
-
Association of blood vitamin A with osteoarthritis: a nationally representative cross-sectional study.Front Nutr. 2024 Nov 5;11:1459332. doi: 10.3389/fnut.2024.1459332. eCollection 2024. Front Nutr. 2024. PMID: 39564209 Free PMC article.
-
Meta-analysis of the synergistic effect of traditional Chinese medicine compounds combined with conventional Western medicine in the treatment of osteoporosis.Front Endocrinol (Lausanne). 2025 May 29;16:1606753. doi: 10.3389/fendo.2025.1606753. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40510481 Free PMC article.
-
Yigu decoction regulates plasma miRNA in postmenopausal osteoporosis patients: a randomized controlled trial.Front Pharmacol. 2024 Nov 6;15:1460906. doi: 10.3389/fphar.2024.1460906. eCollection 2024. Front Pharmacol. 2024. PMID: 39568587 Free PMC article.
-
Neutrophil extracellular traps drive osteoporosis via NCF2-dependent signaling: integrated transcriptomics with mechanistic validation.Redox Rep. 2025 Dec;30(1):2534745. doi: 10.1080/13510002.2025.2534745. Epub 2025 Jul 22. Redox Rep. 2025. PMID: 40696520 Free PMC article.
-
Osteoporosis treatment: current drugs and future developments.Front Pharmacol. 2024 Aug 12;15:1456796. doi: 10.3389/fphar.2024.1456796. eCollection 2024. Front Pharmacol. 2024. PMID: 39188952 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous